HIM
LGND icon

Hillsdale Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Hillsdale Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$307K Buy
1,540
+1,500
+3,750% +$297K 0.01% 504
2025
Q4 		$7.56K Buy
+40
New +$7.69K ﹤0.01% 620
2024
Q2 		– Sell
-45,032
Closed -$3.29M – 645
2024
Q1 		$3.29M Buy
45,032
+3,500
+8% +$258K 0.26% 156
2023
Q4 		$2.97M Sell
41,532
-6,100
-13% -$360K 0.24% 157
2023
Q3 		$2.85M Sell
47,632
-6,100
-11% -$401K 0.26% 144
2023
Q2 		$3.87M Buy
+53,732
New +$4.03M 0.36% 120

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Hillsdale Investment Management's LGND Position: Q1 2026 in Review

Hillsdale Investment Management increased its Ligand Pharmaceuticals (LGND) stake by 3,750% in Q1 2026, buying an estimated $297K and bringing the position to 1,540 shares worth $307K. The position accounts for 0.01% of the portfolio, ranked #504.

Hillsdale Investment Management first reported a position in LGND in Q2 2023 and has held it in 6 quarters since. The position peaked at $3.87M in Q2 2023. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Hillsdale Investment Management held 1,540 shares of Ligand Pharmaceuticals worth $307K as of Q1 2026.
  • Hillsdale Investment Management bought 1,500 Ligand Pharmaceuticals shares in Q1 2026, an estimated $297K.
  • Ligand Pharmaceuticals made up 0.01% of Hillsdale Investment Management's portfolio in Q1 2026, its #504 holding.
  • Hillsdale Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2023 and has held it in 6 quarters since.
  • Hillsdale Investment Management's Ligand Pharmaceuticals position peaked at $3.87M in Q2 2023.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.